Outcome analysis for conservative management of Peyronie's disease

被引:20
|
作者
Hashimoto, K [1 ]
Hisasue, SI [1 ]
Kato, R [1 ]
Kobayashi, K [1 ]
Shimizu, T [1 ]
Tsukamoto, T [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Urol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan
关键词
conservative management; Peyronie's disease; vitamin E;
D O I
10.1111/j.1442-2042.2006.01270.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: We retrospectively analysed the outcomes of conservative management of Peyronie's disease and determined the factors predicting successful outcome. Methods: The study involved 31 patients with Peyronie's disease who were treated at our institute between 1985 and 2003. We assessed the efficacy of vitamin E for the improvement of the symptoms, and the factors which contributed to successful outcome with conservative management using multivariate analysis. Results: There was no statistically significant difference in the relief rate between the vitamin E and no-medication groups. The overall estimated relief rate was 67.5% at 2 years from presentation. The multivariate analysis revealed plaque size to be the only significant factor predicting the relief from all symptoms in patients with conservative management. The rate was 100% in patients having a plaque size of 20 mm or smaller and 20.0% in those having a size of larger than 20 mm (P = 0.005). Conclusions: We could not confirm the benefit of vitamin E for Peyronie's disease. Plaque size was the only significant factor predicting the relief from all symptoms. Patients with larger plaque might fail to respond to the conservative management.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [41] Are the current conservative treatments for Peyronie's disease evidence-based?
    Gontero, P
    Frea, B
    BJU INTERNATIONAL, 2004, 94 (01) : 3 - 4
  • [42] Global Perspective on the Management of Peyronie's Disease
    da Silva, Gabriel Veber Moises
    Davila, Francisco Javier
    Rosito, Tiago Elias
    Martins, Francisco E.
    FRONTIERS IN REPRODUCTIVE HEALTH, 2022, 4
  • [43] Peyronie's disease: epidemiology, diagnosis, and management
    Miner, Martin M.
    Seftel, Allen D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (01) : 113 - 120
  • [44] Peyronie's disease: an update of the medical management
    Maan, Z
    Arya, M
    Shergill, I
    Joseph, JV
    Patel, HRH
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 799 - 805
  • [45] Management of Peyronie's disease with penile prostheses
    Mulcahy, JJ
    Wilson, SK
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2002, 14 (05) : 384 - 388
  • [46] LONG-TERM PATIENT REPORTED OUTCOMES IN MEN WITH PEYRONIE'S DISEASE WHO UNDERGO CONSERVATIVE MANAGEMENT
    Capoccia, Edward
    Ziegelmann, Matthew
    Emerson, Jacob
    Ofori-Marfoh, Claudia
    Lankford, Joseph
    Levine, Laurence
    JOURNAL OF UROLOGY, 2019, 201 (04): : E950 - E950
  • [47] Venous patch graft for Peyronie's disease. Part II: Outcome analysis
    El-Sakka, AI
    Rashwan, HM
    Lue, TF
    JOURNAL OF UROLOGY, 1998, 160 (06): : 2050 - 2053
  • [48] Bibliometric analysis of most cited Peyronie's disease and its management publications
    Sahin, Mehmet Fatih
    Dogan, Cagri
    Akgul, Murat
    Yazici, Cenk Murat
    Seramet, Serkan
    Dayisoylu, Hulusi Sitki
    FRONTIERS IN SURGERY, 2024, 11
  • [49] Corporoplasty for Peyronie's Disease ( IPP, Peyronie's Disease)
    Giessing, M.
    Albers, P.
    AKTUELLE UROLOGIE, 2017, 48 (03) : 256 - 260
  • [50] Review of current nonsurgical management of Peyronie's disease
    L A Levine
    International Journal of Impotence Research, 2003, 15 : S113 - S120